Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Saturday, September 18, 2021 6:41:39 PM
... the proof is mounting that it's downright toxic ... and Fauci knew it.
Major hospital Administrator in a very large Brooklyn Hospital told me at a meeting when I asked what he thought of Remdesivir as a therapeutic...that Clinicians were experiencing many Remedsivir users returning to the hospital with liver and kidney damage...and it was an unspoken concern regarding use of Remedesivir ... but of course "if it saved lives vs liver damage...what choice was there"
IMO...now they will have a choice...BRILACIDIN...
AND...
IMO...with good "actual" results...as PR'd..."Inhaler" would be on the table from interested parties.
Now we are learning Fauci's science project (Remdesivir) which could never achieve efficacy for any indication... Actually Failed. Fauci changed TOP-Line requirements 14 days before the trial was ending...to a new bogus "Top-line" result...so it would not fail once more. In fact, now we know, it never reached the original goal of actually saving lives...
GILEAD is screwed...They desperately need to replace Veklury(REMDESIVIR)... IMO they are like a feral cat sitting at the back door of IPIX waiting for its new meal...BRILACIDIN.
The question is what will BRILACIDIN cost them?
Remember...its all about the science and clinical trials proving out what the RBL's learned and believe...
BRILACIDIN ...is the KEY!
IMO with and via TOP-LINE RESULTS of Brilacidin/Covid-19, we will soon receive CONFIRMATION OF DeGRADO THESIS ...and it will be exactly what Dr. DeGrado and the Polymedix team observed as supporting the efficacy of Brilacidin through its mechanism of producing the destruction of both Bacteria and Virus envelope cells (which Covid-19 and all Mutations are)...on contact!
There was commentary in Polymedix PR's and conferences... that Brilacidin was designed to attract negatively charged envelope cells...and upon contact "pop the dell, like a pin pops a balloon"...but it is not a "by chance" contact with the cells and their destruction would occur...
(IMMEDIATE AND TOTAL DESTRUCTION OF THE VIRUS ON CONTACT IS THE ONLY WAY TO GUARANTEE THE ELIMINATION OF THE ABILITY OF THE COVIE AND ITS VARIANTS TO MUTATE!)
The two (Brilacidin and Envelope Bacteria/Viral Cells) in "proximity" of one another, causes a "magnetic" effect...between the targeted cells (bacterial or viral cells) to be destructed and Brilacidin, i.e. bad cells are "attracted" to Brilacidin.
Add to that...the Systemic IV delivery (especially 5 days in a row)...IMO can show in the Clinical Trials...a very dramatic effect and significant efficacy against Covid-19 and its Variants (Russia had Delta Variant toward the end of trials)...
We should not be surprised and should not forget that...Brilacidin was "INTENTIONALLY DESIGNED" to work as described in the above...it just wasn't "Discovered" to "possibly" do it.
Additionally, with Brilacidin's superior SI, I would not be surprised if we learn that the DAILY DOSAGE (given 5 days in a row...for 75% of the patients) of Brilacidin/Covid-19 was the same as the ABSSSI Trials...which demonstrated superior efficacy over the SOC with only ONE IV DOSE.
In other words... with Brilacidin SI so high...it would not be surprising that the FDA would "let it rip" against Covid-19.
We will soon know the results! Keep smiling!
...and KNOW WHAT YOU OWN!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM